Boehringer Ingelheim achieves major milestone in chronic kidney disease aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim today announced promising 14week Phase II data for BI 690517 a novel selective aldosterone synthase inhibitor ASi.

Related Keywords

Germany ,Ingelheim ,Rheinland Pfalz ,United States ,American ,Carinne Brouillon ,Katherine Tuttle ,Nephrology Division ,Kidney Research Institute ,University Of Washington ,American Society Of Nephrology ,Boehringer Ingelheim ,Oxford Population Health ,Oxford Population ,American Society ,Kidney Week ,Principal Study Investigator ,Human Pharma ,Media Contact ,Ten Wolde ,Media Relations ,Boehringer Ingelheim Dr Katherine Tuttle Carinne Brouillon Oxford Population Health Phase Iii Easikidney Ii Trial Bi 690517 American Society Of Nephrology Asn Kidney Week Chronic Disease Aldosterone Synthase Inhibitor Asi Albuminuria Damage Empagliflozin Sodium Glucose Cotransporter Sglt2 Organ Serum Potassium Hyperkalemia Uacr Cardiorenalmetabolic Conditions Healthcare Systems ,